OLDWICK, N.J., May 28, 2020 /PRNewswire/ -- Provention Bio,
Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to
intercepting and preventing immune-mediated diseases, today
announced that management will present at the Jefferies Virtual
Healthcare Conference on Thursday, June 4, 2020, at 8:30
am E.T.
A webcast of the presentation can be accessed by visiting the
Events and Webcasts section of the Company's website:
http://investors.proventionbio.com/events. The webcast will
be archived on the Company's website for 90 days following the
presentation.
About Provention Bio, Inc.
Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical
company leveraging a drug development strategy focused on the
prevention or interception of immune-mediated disease. Provention's
mission is to source, transform and develop therapeutic candidates
targeting the high morbidity, mortality and escalating costs of
autoimmune diseases. Provention's portfolio includes PRV-031
(teplizumab), a pre-commercial-stage candidate that has been shown
to delay the onset of end-stage type one diabetes (T1D) in at-risk
individuals with pre-symptomatic disease. The Company's portfolio
includes additional clinical-stage product development candidates
currently in development for other autoimmune diseases,
including celiac disease and lupus.
Investors:
Sam Martin, Argot Partners
sam@argotpartners.com
212-600-1902
Media:
Lori Rosen, LDR Communications
lori@ldrcommunications.com
917-553-6808
View original content to download
multimedia:http://www.prnewswire.com/news-releases/provention-bio-to-present-at-the-jefferies-virtual-healthcare-conference-301066496.html
SOURCE Provention Bio, Inc.